KEAP1 and hepatocellular carcinoma: Moreover, loss of KEAP1 activity through somatic mutations has been reported in HCC,14, 15, 19 indicating that constitutive activation of NRF2 and aberrant NRF2 activation causes chemotherapeutic resistance in HCC19 and other cancers.20